CLL Society joined fellow advocates in expressing the need for Centers for Medicare & Medicaid Services (CMS) to implement proactive guardrails around Part D health plans’ use of utilization management (UM) tools in light of the coming Part D redesign. In other words, when Part D plans become responsible for more of the drug cost that patients need in 2025, CMS must make sure those same plans do not alter or reduce patients’ access to those drugs.
Appropriate use of UM, full disclose and transparency on their policies, and sufficient education for patients on appeals processes will be critical. The impact on patients must be considered as the Inflation Reduction Act (IRA) is implemented.
